Literature DB >> 15802497

Adrenocorticotropin evokes transient elevations in intracellular free calcium ([Ca2+]i) and increases basal [Ca2+]i in resting chondrocytes through a phospholipase C-dependent mechanism.

Jodi F Evans1, Chwan-L Shen, Simcha Pollack, John F Aloia, James K Yeh.   

Abstract

Both clinical and in vitro evidence points to the involvement of the melanocortin peptide, ACTH, in the terminal differentiation of chondrocytes. Terminal differentiation along the endochondral pathway is responsible for linear growth, but also plays a role in osteoarthritic cartilage degeneration. Chondrocyte terminal differentiation is associated with an incremental increase in chondrocyte basal intracellular free calcium ([Ca(2+)](i)), and ACTH agonism of melanocortin receptors is known to mobilize [Ca(2+)](i.) Using differentiated resting chondrocytes highly expressing type II collagen and aggrecan, we examined the influence of both ACTH and dexamethasone treatment on matrix gene transcription and [Ca(2+)](i). Resting chondrocytes treated concurrently with dexamethasone and ACTH expressed matrix gene transcripts in a pattern consistent with that of rapid terminal differentiation. Using the fluorescent Ca(2+) indicator, fura-2, we determined that ACTH evokes transient increases in [Ca(2+)](i) and elevates basal Ca(2+) levels in resting chondrocytes. The transient increases were initiated intracellularly, were abrogated by the phospholipase C-specific inhibitor, U73122, and were partly attenuated by myo-inositol 1,4,5-triphosphate receptor inhibition via 10 mm caffeine. The initial intracellular release also resulted in store-operated calcium entry, presumably through store-operated channels. Dexamethasone priming increased both the initial ACTH-evoked [Ca(2+)](i) release and the subsequent store-operated calcium entry. These data demonstrate roles for ACTH and glucocorticoid in the regulation of chondrocyte terminal differentiation. Because the actions of ACTH are mediated through known G protein-coupled receptors, the melanocortin receptors, these data may provide a new therapeutic target in the treatment of growth deficiencies and cartilage degeneration.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15802497     DOI: 10.1210/en.2004-1612

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  8 in total

1.  Functional melanocortin-2 receptors are expressed by mouse aorta-derived mesenchymal progenitor cells.

Authors:  Jodi F Evans; Anne Fernando; Louis Ragolia
Journal:  Mol Cell Endocrinol       Date:  2012-01-27       Impact factor: 4.102

Review 2.  Role of proopiomelanocortin-derived peptides and their receptors in the osteoarticular system: from basic to translational research.

Authors:  Markus Böhm; Susanne Grässel
Journal:  Endocr Rev       Date:  2012-06-26       Impact factor: 19.871

3.  Systemic and local ACTH produced during inflammatory states promotes osteochondrogenic mesenchymal cell differentiation contributing to the pathologic progression of calcified atherosclerosis.

Authors:  Jodi F Evans; Louis Ragolia
Journal:  Med Hypotheses       Date:  2012-09-29       Impact factor: 1.538

4.  Phospholipases of mineralization competent cells and matrix vesicles: roles in physiological and pathological mineralizations.

Authors:  Saida Mebarek; Abdelkarim Abousalham; David Magne; Le Duy Do; Joanna Bandorowicz-Pikula; Slawomir Pikula; René Buchet
Journal:  Int J Mol Sci       Date:  2013-03-01       Impact factor: 5.923

5.  ACTH promotes chondrogenic nodule formation and induces transient elevations in intracellular calcium in rat bone marrow cell cultures via MC2-R signaling.

Authors:  Jodi F Evans; Sylvana Rodriguez; Louis Ragolia
Journal:  Cell Tissue Res       Date:  2013-01-29       Impact factor: 5.249

6.  α-Melanocyte-stimulating-hormone (α-MSH) modulates human chondrocyte activation induced by proinflammatory cytokines.

Authors:  Franco Capsoni; Anna Maria Ongari; Caterina Lonati; Riccardo Accetta; Stefano Gatti; Anna Catania
Journal:  BMC Musculoskelet Disord       Date:  2015-06-21       Impact factor: 2.362

7.  Genetic variants in the ITPR2 gene are associated with Kashin-Beck Disease in Tibetan.

Authors:  Xue He; Mei Bai; Ming Liu; Li Wang; Yongjun He; Hao Rong; Dongya Yuan; Tianbo Jin
Journal:  Mol Genet Genomic Med       Date:  2019-05-07       Impact factor: 2.183

Review 8.  Caffeine, a Risk Factor for Osteoarthritis and Longitudinal Bone Growth Inhibition.

Authors:  María Guillán-Fresco; Eloi Franco-Trepat; Ana Alonso-Pérez; Alberto Jorge-Mora; Miriam López-Fagúndez; Andrés Pazos-Pérez; Oreste Gualillo; Rodolfo Gómez
Journal:  J Clin Med       Date:  2020-04-18       Impact factor: 4.241

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.